Therefore, transient expression of CART-secreted aIL6 and IL1RA could minimize potential risk of increasing possibility of infection during CART treatment by impairing patients’ immunity through IL6 and IL1 sigaling blockade. The gene discussed is IL6R; the disease is infection.